Therefore, PD-1/PD-L1 signaling is more specific to tumor than CTLA-4 signaling, and inhibitors of PD-1/PD-L1 may cause less damage to healthy tissue (Boussiotis, 2016; Minion and Tewari, 2018) (Figure 1). Here, CTLA4 is linked to neoplasm.